Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002231
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Safety and Effects of Giving a New HIV Vaccine GENEVAX-HIV to HIV-Negative Volunteers
Sponsor:
Wyeth-Lederle Vaccines
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
GENEVAX-HIV APL 400-003 a Candidate DNA Vaccine A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers
Status:
COMPLETED
Status Verified Date:
2000-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe to give GENEVAX-HIV a new HIV vaccine to HIV-negative volunteers This study will also look at how this vaccine affects the immune system of these volunteers
Detailed Description:
In this open-label study volunteers are given an intramuscular injection of GENEVAX-HIV vaccine using the Biojector 2000 Safety measures and immune response are assessed accordingly
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 04400-003-04 | None | None | None |